BioPharm Weekly News Roundup—Week of Oct. 20, 2025

Welcome to the BioPharm International® weekly news roundup for the week of Oct. 20, 2025. In this video feature, the editors highlight each week’s industry news in an easy-to-consume, fun format. New roundups will drop every Friday, so be sure to come back each week. And be sure to check the links below for more in-depth coverage of each story.

The Committee for Medicinal Products for Human Use’s recommendation of Saphnelo (anifrolumab) supports self-administered subcutaneous lupus treatment, boosting patient access and reducing harmful corticosteroid reliance.

CPHI Frankfurt 2025 will feature a leadership summit and tracks focusing on AI, sustainability, and global pharmaceutical supply chain resilience.

Avantor and p-Chip embed digital microtransponders into labware, ensuring secure chain-of-identity and enhanced traceability for individualized cell and gene therapies.

Global PROCLIPI data confirms mogamulizumab provides a significant overall survival advantage for advanced cutaneous T-cell lymphoma patients.

Orion licensed an Abzena monoclonal antibody utilizing integrated developability (CHAb technology) to streamline manufacturing and de-risk oncology biopharmaceutical development.

SK pharmteco invested $6.1 million to expand US peptide purification and synthesis capacity, overcoming supply chain bottlenecks for targeted therapeutics.